NCT01846351

Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 16 (actual)
• Sponsor: New England Retina Associates · Academic / Other
• Sex: All
• Age: 58 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Detailed description

Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Conditions

• Epiretinal Membrane
• Age Related Macular Degeneration

Timeline

• Start date: 2006-07-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2013-05-03
• Last updated: 2013-05-03